Literature DB >> 17726707

The increased cost of complications in children with status asthmaticus.

Christopher L Carroll1, Aaron R Zucker.   

Abstract

Status asthmaticus is one of the most common causes of admission to a pediatric intensive care unit (PICU). There is little published data, however, examining the complications associated with the treatment of status asthmaticus in children in the PICU. Our hypothesis was that children experiencing a complication would have an increased duration of hospitalization for status asthmaticus. We performed a retrospective review of the complication profile and hospital course of all children admitted to a PICU with status asthmaticus over a 9 years period. Twenty-two (8%) of the 293 children admitted to the ICU with status asthmaticus experienced one or more complications during their treatment. The most common complications were aspiration pneumonia, ventilator-associated pneumonia, pneumomediastinum, pneumothorax, and rhabdomyolysis. Intubated children were significantly more likely than non-intubated children to experience a complication (RR 15.3; 95% CI 6.7-35). Fifteen (42%) of the 36 intubated children experienced a complication. Intubated children experiencing a complication had significantly longer duration of mechanical ventilation (163 +/- 169 hr vs. 66 +/- 65 hr, P = 0.03), ICU length of stay (237 +/- 180 hr vs. 124 +/- 86 hr, P = 0.02) and hospital charges (US dollars 117,184 +/- 111,191 vs. US dollars 38,788 +/- 27,784; P = 0.001) than intubated children not experiencing a complication. In this review, complications were associated with increased morbidity and duration of hospitalization in children with status asthmaticus, particularly in those intubated as part of their therapy. This suggests that intubation and mechanical ventilation itself may increase the risk of developing a complication in this population. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17726707     DOI: 10.1002/ppul.20682

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  8 in total

1.  Rhabdomyolysis. The role of diagnostic and prognostic factors.

Authors:  Eran Keltz; Fahmi Yousef Khan; Gideon Mann
Journal:  Muscles Ligaments Tendons J       Date:  2014-02-24

2.  Isoflurane for life-threatening bronchospasm: a 15-year single-center experience.

Authors:  David A Turner; David Heitz; Mehrengise K Cooper; P Brian Smith; John H Arnold; Scot T Bateman
Journal:  Respir Care       Date:  2012-03-13       Impact factor: 2.258

3.  Factors Associated with Failure of Intermittent Nebulization with Short-Acting Beta-Agonists in Children with Severe Asthma Exacerbation.

Authors:  Prapasri Kulalert; Phichayut Phinyo; Jayanton Patumanond; Chutima Smathakanee; Wantida Chuenjit; Sira Nanthapisal
Journal:  J Asthma Allergy       Date:  2020-08-25

4.  Rising charges and costs for pediatric catheter ablation.

Authors:  Kristin M Burns; Frank Evans; Gail D Pearson; Charles I Berul; Jonathan R Kaltman
Journal:  J Cardiovasc Electrophysiol       Date:  2012-10-15

5.  Outcome of children with life-threatening asthma necessitating pediatric intensive care.

Authors:  Kam-Lun Hon; Wing-Sum Winnie Tang; Ting-Fan Leung; Kam-Lau Cheung; Pak-Cheung Ng
Journal:  Ital J Pediatr       Date:  2010-07-06       Impact factor: 2.638

Review 6.  Potential factors involved in the causation of rhabdomyolysis following status asthmaticus.

Authors:  Hongmei Qiao; Huanji Cheng; Li Liu; Jianing Yin
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-22       Impact factor: 3.406

7.  Continuous versus intermittent short-acting β2-agonists nebulization as first-line therapy in hospitalized children with severe asthma exacerbation: a propensity score matching analysis.

Authors:  Prapasri Kulalert; Phichayut Phinyo; Jayanton Patumanond; Chutima Smathakanee; Wantida Chuenjit; Sira Nanthapisal
Journal:  Asthma Res Pract       Date:  2020-07-02

8.  Asthma changes at a pediatric intensive care unit after 10 years: Observational study.

Authors:  Ayman A Al-Eyadhy; Mohamad-Hani Temsah; Ali A N Alhaboob; Abdulmalik K Aldubayan; Nasser A Almousa; Abdulrahman M Alsharidah; Mohammed I Alangari; Abdulrahman M Alshaya
Journal:  Ann Thorac Med       Date:  2015 Oct-Dec       Impact factor: 2.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.